Atlas of Exosomal microRNAs Secreted From Human iPSC-Derived Cardiac Cell Types. Circulation. 2020;142(18):1794-1796.
A computational model of induced pluripotent stem-cell derived cardiomyocytes for high throughput risk stratification of KCNQ1 genetic variants. PLoS Comput Biol. 2020;16(8):e1008109..
Human induced pluripotent stem cells for modelling metabolic perturbations and impaired bioenergetics underlying cardiomyopathies. Cardiovasc Res. 2020..
Induced Pluripotent Stem Cells as a Platform to Understand Patient-Specific Responses to Opioids and Anaesthetics. Br J Pharmacol. 2020..
Intrinsic Endocardial Defects Contribute to Hypoplastic Left Heart Syndrome. Cell Stem Cell. 2020.
Metabolic Maturation Media Improve Physiological Function of Human iPSC-Derived Cardiomyocytes. Cell Rep. 2020;32(3):107925.
Modeling Secondary Iron Overload Cardiomyopathy with Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Cell Rep. 2020;32(2):107886.
Single-cell protein expression of hiPSC-derived cardiomyocytes using Single-Cell Westerns. J Mol Cell Cardiol. 2020..
Wnt Activation and Reduced Cell-Cell Contact Synergistically Induce Massive Expansion of Functional Human iPSC-Derived Cardiomyocytes. Cell Stem Cell. 2020;27(1):50-63.e5.
A computational model of induced pluripotent stem-cell derived cardiomyocytes incorporating experimental variability from multiple data sources. J Physiol. 2019..
Generation of Endothelial Cells From Human Pluripotent Stem Cells. Arterioscler Thromb Vasc Biol. 2019;39(7):1317-1329..
Induced Pluripotent Stem Cells as a Novel Cancer Vaccine. Expert Opin Biol Ther. 2019..
Modelling diastolic dysfunction in induced pluripotent stem cell-derived cardiomyocytes from hypertrophic cardiomyopathy patients. Eur Heart J. 2019.
NanoMEA: a tool for high-throughput, electrophysiological phenotyping of patterned excitable cells. Nano Lett. 2019.
Splice-Junction-Based Mapping of Alternative Isoforms in the Human Proteome. Cell Rep. 2019;29(11):3751-3765.e5..
Towards Precision Medicine With Human iPSCs for Cardiac Channelopathies. Circ Res. 2019;125(6):653-658..
The West coast regional safety pharmacology society meeting update: Filling translational gaps in safety assessment. J Pharmacol Toxicol Methods. 2019:106582.
Workshop Report: FDA Workshop on Improving Cardiotoxicity Assessment With Human-Relevant Platforms. Circ Res. 2019;125(9):855-867.
Disease modelling and drug discovery for hypertrophic cardiomyopathy using pluripotent stem cells: how far have we come?. Eur Heart J. 2018..
Genome Editing of Induced Pluripotent Stem Cells to Decipher Cardiac Channelopathy Variant. J Am Coll Cardiol. 2018;72(1):62-75..
Progress, obstacles, and limitations in the use of stem cells in organ-on-a-chip models. Adv Drug Deliv Rev. 2018..
Systems-Wide Approaches in Induced Pluripotent Stem Cell Models. Annu Rev Pathol. 2018..
Adult Stem Cell Therapy and Heart Failure, 2000 to 2016: A Systematic Review. JAMA Cardiol. 2016..
Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nat Med. 2016.